Literature DB >> 22335459

CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.

S-W Tang1, X-Z Lv, Y Zhang, S-S Wu, Z-R Yang, Y-Y Xia, D-H Tu, P-Y Deng, Y Ma, D-F Chen, S-Y Zhan.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The pathogenic mechanism of antituberculosis drug-induced hepatotoxicity (ATDH) is thought to involve drug-metabolizing enzymes including N-acetyl transferase2 (NAT2), cytochrome P4502E1 (CYP2E1) and glutathione S-transferase (GST) M1, T1. The associations between genetic polymorphisms of those genes and ATDH have been reported but with inconsistent results. Moreover, most studies were hospital-based retrospective studies and not prospective. We aimed to investigate possible associations of CYP2E1, GSTM1 and GSTT1 genetic polymorphisms with ATDH using a more robust case-control study nested in a population-based prospective antituberculosis treatment cohort.
METHODS: A total of 4304 patients with smear-positive tuberculosis (TB) who received standard short-course chemotherapy were monitored for 6-9 months. Incidence density sampling method was adopted to select controls and 4 : 1 matched with each ATDH cases by age (± 5 years), sex, treatment history, disease severity and drug dosage. The CYP2E1, GSTM1 and GSTT1 polymorphisms were genotyped using PCR-RFLP and multiplex PCR methods. Conditional logistic regression model was used to calculate odds ratio (OR) and 95% confidence interval (CI), as well as corresponding P-values. RESULTS AND DISCUSSION: A total of 89 ATDH cases and 356 controls were included in this study. There was no statistically significant association between CYP2E1 RsaI c1/c1 genotype or DraI C/C genotype and ATDH (OR = 0·99, 95% CI:0·62-1·59; OR = 1·13, 95% CI: 0·40-3·20, respectively) compared with CYP2E1 RsaI c1/c2 or c2/c2 genotypes or DraI D/D genotype, or between GSTM1/GSTT1 null genotypes and ATDH (OR = 1·22, 95% CI: 0·76-1·96; OR = 0·96, 95% CI: 0·60-1·52, respectively) compared with non-null genotypes. WHAT IS NEW AND
CONCLUSION: This is the first study of the involvement of CYP2E1, GSTM1 and GSTT1 genetic polymorphisms in ATDH using a nested case-control population-based prospective cohort design. We could not confirm positive associations of genetic polymorphisms of CYP2E1 RsaI, CYP2E1 DraI, GSTM1 null and GSTT1 null with ATDH reported by various groups, in our Chinese TB population.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22335459     DOI: 10.1111/j.1365-2710.2012.01334.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  15 in total

1.  Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.

Authors:  N Ben Fredj; R Gam; E Kerkni; A Chaabane; Z Chadly; N Boughattas; K Aouam
Journal:  Pharmacogenomics J       Date:  2016-04-19       Impact factor: 3.550

2.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

3.  Association between CYP2E1 and GOT2 gene polymorphisms and susceptibility and low-dose N,N-dimethylformamide occupational exposure-induced liver injury.

Authors:  Haiyue Jiang; Xiaoyue Zhang; Jiayang Shen; Yu Zhang; Yiyang Gu; Tian Tian; Minjie Chu; Xun Zhuang; Yulong Lian
Journal:  Int Arch Occup Environ Health       Date:  2019-04-16       Impact factor: 3.015

Review 4.  GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.

Authors:  C Li; J Long; X Hu; Y Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-02       Impact factor: 3.267

Review 5.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

6.  Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.

Authors:  Fang Liu; An-xia Jiao; Xi-rong Wu; Wei Zhao; Qing-qin Yin; Hui Qi; Wei-wei Jiao; Jing Xiao; Lin Sun; Chen Shen; Jian-ling Tian; Dan Shen; Evelyne Jacqz-Aigrain; A-dong Shen
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

Review 7.  Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.

Authors:  Alexander D Roth; Moo-Yeal Lee
Journal:  Biomed Res Int       Date:  2017-01-04       Impact factor: 3.411

8.  Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.

Authors:  Yu Cai; JiaYong Yi; ChaoHui Zhou; XiZhong Shen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

9.  The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Authors:  Yang Xiang; Long Ma; Weidong Wu; Wei Liu; Yongguang Li; Xia Zhu; Qian Wang; Jinfeng Ma; Mingqin Cao; Qian Wang; Xuemei Yao; Lei Yang; Atikaimu Wubuli; Corinne Merle; Paul Milligan; Ying Mao; Jiayi Gu; Xiumei Xin
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis.

Authors:  Marty Richardson; Jamie Kirkham; Kerry Dwan; Derek J Sloan; Geraint Davies; Andrea L Jorgensen
Journal:  Syst Rev       Date:  2018-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.